NPC Welcomes GlaxoSmithKline as New Member
WASHINGTON, July 22 /PRNewswire-USNewswire/ -- National Pharmaceutical Council (NPC) President Dan Leonard today welcomed GlaxoSmithKline (GSK) as the latest member of the health policy research organization.
"NPC is focused on bringing together thought leaders and supporting the research to inform important health policy discussions related to the generation and use of comparative evidence. This role is particularly critical given the creation of the Patient-Centered Outcomes Research Institute and our nation's increasing use of comparative effectiveness to support health care decision making," said Leonard. "We are very pleased to welcome GSK in NPC membership as we address these important issues."
GSK is one of the world's leading research-based pharmaceutical and healthcare companies with U.S. headquarters in Research Triangle Park, North Carolina. Jack Bailey, Sr. Vice President, Private, Public and Institutional Customers, will serve as GSK's representative on NPC's Board of Directors.
"As the nation moves forward with the implementation of health care reform, NPC's research provides policy makers and implementers with keen insight on comparative effectiveness research and health and wellness issues," said Bailey. "I welcome the opportunity to work with NPC and its staff as they move forward with these and other research areas impacting the pharmaceutical industry."
In serving on NPC's Board, Bailey will join top executives from the leading research-based pharmaceutical companies, including Abbott Laboratories, AstraZeneca LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eisai inc., Johnson & Johnson, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Otsuka America Pharmaceutical, Inc., Pfizer Inc, sanofi-aventis, Takeda Pharmaceuticals North America, Inc., and Teva Neuroscience.
About the National Pharmaceutical Council
NPC's overarching mission is to sponsor and conduct scientific analyses of the appropriate use of biopharmaceuticals and the clinical and economic value of innovation. The organization's strategic focus is on evidence-based medicine (EBM) for health care decision-making, to ensure that patients have access to high-quality care. NPC was established in 1953 and is supported by the nation's major research-based pharmaceutical companies. As a research and education organization, NPC does not take positions on legislation. For more information, visit www.npcnow.org.
SOURCE National Pharmaceutical Council